Product Pathways - Development
NKX2.5 Antibody #5444
|5444S||100 µl (10 western blots)||---||In Stock||---|
|5444||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Specificity / Sensitivity
NKX2.5 Antibody detects endogenous levels of total NKX2.5 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala71 of human NKX2.5 protein. Antibodies are purified by protein A and peptide affinity chromatography.
NKX2.5 is a member of the NKX homeobox transcription factor family. NKX2.5 plays an essential role in heart development and is among the earliest factors expressed in the cardiac lineage in developing embryos. Targeted disruption of the murine Nkx2.5 gene results in abnormal heart morphogenesis, severe growth retardation, and embryonic lethality around E9.5 (1,2). Mutations in NKX2.5 are likewise associated with several congenital heart conditions, such as atrial defect with atrioventricular conduction defects (ASD-AVCD) and Tetralogy of Fallot (TOF) (3,4). Transcriptional activation of NKX2.5 is also associated with some B and T cell leukemias that result from chromosomal translocation (5-8).
- Lyons, I. et al. (1995) Genes Dev 9, 1654-66.
- Tanaka, M. et al. (1999) Development 126, 1269-80.
- Benson, D.W. et al. (1999) J Clin Invest 104, 1567-73.
- Reamon-Buettner, S.M. and Borlak, J. (2010) Hum Mutat 31, 1185-94.
- Nagel, S. et al. (2003) Cancer Res 63, 5329-34.
- Przybylski, G.K. et al. (2006) Haematologica 91, 317-21.
- Nagel, S. et al. (2007) Cancer Res 67, 1461-71.
- Su, X. et al. (2008) Haematologica 93, 1081-5.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.